A NEW LOOK AT THE BIOMARKER ROLE OF PROSTANOIDS – COMMON LINKS  IN THE PATHOGENESIS OF UROLOGICAL CANCERS AND COVID-19

V. N. Komarevtsev; K. V. Balabanova; I. V. Kalinin; I. O. Komarevtseva; I. A. Vyshnitska; K. V. Shipilov; N. M. Seryogina

Article

World of Medicine and Biology / №2(88), 2024 / A NEW LOOK AT THE BIOMARKER ROLE OF PROSTANOIDS – COMMON LINKS IN THE PATHOGENESIS OF UROLOGICAL CANCERS AND COVID-19

V. N. Komarevtsev, K. V. Balabanova, I. V. Kalinin, I. O. Komarevtseva, I. A. Vyshnitska, K. V. Shipilov, N. M. Seryogina

A NEW LOOK AT THE BIOMARKER ROLE OF PROSTANOIDS – COMMON LINKS IN THE PATHOGENESIS OF UROLOGICAL CANCERS AND COVID-19

About the author:	V. N. Komarevtsev, K. V. Balabanova, I. V. Kalinin, I. O. Komarevtseva, I. A. Vyshnitska, K. V. Shipilov, N. M. Seryogina
Heading	CLINICAL MEDICINE
Type of article	Scentific article
Annotation	The purpose of the study was a comparative analysis of the level of eicosanoid excretion in urine in patients with COVID-19 and tumors of the kidneys, bladder and prostate gland, which, in our opinion, will make it possible to establish some common links in the pathogenesis of tumor lesions and COVID-19. Urinary excretion of PGI2, PGE2, TxB2, PGF2α in patients with COVID-19 , as in patients with bladder cancer and prostate cancer is significantly increased. Whereas in patients with kidney cancer without and with metastases, the entire spectrum of prostanoids was significantly reduced. The leading prostanoids in COVID-19 patients were prostacyclin PGI2 and PGE2; in patients with bladder cancer and prostate cancer – PGE2, and in patients with kidney cancer without and with metastases – thromboxane B2.
Tags	prostaglandins and thromboxane,COVID-19,tumors of the kidneys,bladder and prostate gland
Bibliography	Archambault AS, Zaid Y, Rakotoarivelo V, Turcotte C, Doré E, DubucI, et al. High levels of eicosanoids and docosanoids in the lungs of intubated COVID‐19 patients. FASEB J. 2021;35(6):e21666. Biagini D, Oliveri P, Baj A, Gasperina DD, Ferrante FD, Lomonaco T, et al. The effect of SARS-CoV-2 variants on the plasma oxylipins and PUFAs of COVID-19 patients. Prostaglandins Other Lipid Mediat. 2023;169. doi:10.1016/j.prostaglandins.2023.106770 Biswas P, Datta C, Rathi P, Bhattacharjee A. Fatty acids and their lipid mediators in the induction of cellular apoptosis in cancer cells. Prostaglandins Other Lipid Mediat. 2022;160. doi:10.1016/j.prostaglandins.2022.106637 Bohnacker S, Hartung F, Henkel F, Quaranta A, Kolmert J, Priller A, et al. Mild COVID‐19 imprints a long‐term inflammatory eicosanoid‐ and chemokine memory in monocyte‐derived macrophages. Mucosal Immunol. 2022;15(3):515–524. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-838. doi:10.1016/j.kint.2020.03.005 Gadelha LR, Bezerra Costa MJ, Alekrim de Abreu JP, Venancio LP, Fabres-Klein MH, Klein RC, et al. Prostaglandin E2 leukotriene B4 balance and viral load in different clinical stages of COVID-19: a cross-sectional study. Prostaglandins Other lipid mediators. 2024 Feb 10:172:106820. doi: 10.1016/j.prostaglandins.2024.106820. Kiely M, Milne GL, Minas TZ, Dorsey TH, Tang W, Smith CJ, et al. Urinary Thromboxane B2 and Lethal Prostate Cancer in African American Men. J Natl Cancer Inst. 2022;114(1):123–129. doi:10.1093/jnci/djab129 Kiely M, Milne GL, Minas TZ, Dorsey TH, Tang W, Smith CJ, et al. Urinary pge in men with prostate cancers (Basel). 2021;13(16). doi:10.3390/cancers13164073 Kurano M, Jubishi D, Okamoto K, Hashimoto H, Sakai E, Morita Y, et al. Dynamic modulations of urinary sphingolipid and glycerophospholipid levels in COVID-19 and correlations with COVID-19-associated kidney injuries. J Biomed Sci. 2022;29(1). doi:10.1186/s12929-022-00880-5 Meng H, Sengupta A, Ricciotti E, Mrčela A, Mathew D, Mazaleuskaya LL, et al. Deep phenotyping of the lipidomic response in COVID‐19 and non‐COVID‐19 sepsis. Clin Transl Med. 2023;13(11). doi:10.1002/ctm2.1440 Nugent J, Aklilu A, Yamamoto Y, Simonov M, Li F, Biswas A, et al. Assessment of Acute Kidney Injury and Longitudinal Kidney Function after Hospital Discharge among Patients with and without COVID-19. JAMA Netw Open. 2021;4(3). doi:10.1001/jamanetworkopen.2021.1095 Pérez MM, Pimentel VE, Fuzo CA, da Silva-Neto PV, Toro DM, Fraga-Silva TFC, et al. ImmunoCOVID Brazilian Research Consortium. Acetylcholine, fatty acids, and lipid mediators are linked to COVID‐19 severity. J Immunol. 2022;209(2):250–261. Reina-Couto M, Roboredo-Madeira M, Pereira-Terra P, Silva-Pereira C, Martins S, Teixeira-Santos L, et al. Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients. Inflamm Res. 2023;72(3):475–491. doi:10.1007/s00011-022-01682-z Smeitink J, Jiang X, Pecheritsyna S, Renkema H, Van Maanen R, Beyrath J. Hypothesis: mPGES-1-derived prostaglandin E2, a so far missing link in COVID-19 pathophysiology? Preprints. 2020. 2020040180. doi: 10.20944/ preprints202004. 0180.v1. Thulasingam M, Haeggström JZ. Integral Membrane Enzymes in Eicosanoid Metabolism: Structures, Mechanisms and Inhibitor Design. J Mol Biol. 2020;432(18):4999–5022. doi:10.1016/j.jmb.2020.07.020
Publication of the article	«World of Medicine and Biology» №2(88), 2024 year, 86-89 pages, index UDK 616.61-006:616.65+576.367
DOI	10.26724/2079-8334-2024-2-88-86-89